Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia
Qianyi Zhou(Tianjin Medical University), Hairong Lyu(University of Bristol), Xue Bai(Southwest Medical University), Haibo Zhu(Tianjin First Center Hospital), Cuicui Lyu(Tianjin First Center Hospital), Tianle Xie(Nankai University), Yuxin An(Tianjin Medical University), Xia Xiao(Hebei Medical University), Juanxia Meng(Tianjin First Center Hospital), Yu Zhang(Shantou University), Huan Zhang(Tianjin First Center Hospital), Haotian Meng(University of Jinan), Yedi Pu(Tianjin First Center Hospital), Xiaomei Zhang(Tianjin First Center Hospital), Pengjiang Liu(Tianjin First Center Hospital)
Cited by 7
Related Papers
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
|Journal of Hematology & Oncology|2022|149
Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells
|Cell Death and Disease|2013|129
Characterization of Bovine Induced Pluripotent Stem Cells by Lentiviral Transduction of Reprogramming Factor Fusion Proteins
|International Journal of Biological Sciences|2012|80